Compare Avantis International Small Cap Value ETF (AVDV) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avantis International Small Cap Value ETF vs Pfizer Inc — how do they compare? Avantis International Small Cap Value ETF trades at $105.24, while Pfizer Inc trades at $24.26 (market cap $138.21B). The key difference: Pfizer Inc pays a 7.09% dividend while Avantis International Small Cap Value ETF pays none, and Avantis International Small Cap Value ETF is trading nearer its 52-week high, Pfizer Inc nearer its low. Which is the better fit depends on your goals.
| AVDV | PFE | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $110.40 | $28.56 |
52-Week Low | $80.02 | $23.29 |
Market Cap | — | $138.21B |
Volume | — | 29,869,932 |
Enterprise Value | — | $188.87B |
Dividend Yield | — | 7.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AVDV trades at $103.10, down 1.06% with a bearish technical signal from moving averages. Recent news highlights strong 2026 performance with international small-cap value strategies delivering 35% gains while paying dividends. The fund's commodity exposure has cooled after driving outperformance, shifting the forward setup.
The outlook remains mixed with technical indicators signaling caution but positive sentiment around international small-cap value diversification. Key risks include commodity volatility and regional economic exposure, while institutional interest grows with Farther Finance increasing holdings by 165.8% in Q4 2025.
Pfizer (PFE) trades at $24.25, up 0.33% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 EPS of $0.75, beating expectations, and maintains a dividend of $0.43 per share. Recent news highlights Pfizer's focus on its obesity and oncology pipeline, with key catalysts expected in 2026. Financials show revenue of $62.58B in 2025, with a net income margin of 11.83% and a P/E ratio of 18.69.
The outlook for Pfizer is mixed, with analyst consensus leaning toward Hold (58.98%) but a price target of $28.78 suggesting potential upside. Investment opportunities include a strong dividend yield and pipeline advancements, while risks involve patent cliffs and competitive pressures. The stock's current valuation appears reasonable, but execution on pipeline developments is critical for future growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avantis International Small Cap Value ETF
AVDV is an actively managed ETF that targets small-cap value companies in developed markets outside the United States. It uses a systematic, rules-based process to identify firms trading at low valuations with high profitability, aiming to capture the 'size' and 'value' premiums while maintaining broad diversification.
Read more on AVDV →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
